Compugen Ltd. (NASDAQ:CGEN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Compugen Ltd. (NASDAQ:CGEN) have been given an average rating of “Moderate Buy” by the five analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $5.00.

A number of brokerages have recently commented on CGEN. Lake Street Capital began coverage on Compugen in a research note on Tuesday, April 7th. They issued a “buy” rating and a $6.00 price target for the company. Truist Financial raised Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a research note on Monday, April 20th. Leerink Partners lowered their price target on Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, May 21st. Finally, Wall Street Zen cut Compugen from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd.

Compugen Price Performance

Shares of CGEN stock opened at $2.01 on Monday. The stock has a market cap of $190.05 million, a PE ratio of 5.43 and a beta of 2.74. The stock has a 50-day moving average of $2.58 and a 200-day moving average of $2.12. Compugen has a one year low of $1.30 and a one year high of $3.24.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Monday, May 18th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The company had revenue of $2.18 million during the quarter, compared to the consensus estimate of $1.57 million. Compugen had a net margin of 47.97% and a return on equity of 47.72%. As a group, research analysts anticipate that Compugen will post -0.28 earnings per share for the current year.

Institutional Trading of Compugen

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its holdings in Compugen by 12.1% during the 1st quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock worth $3,478,000 after buying an additional 176,088 shares during the period. State Street Corp raised its holdings in shares of Compugen by 3.9% during the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after acquiring an additional 14,701 shares during the period. Jane Street Group LLC lifted its position in Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after acquiring an additional 359,785 shares in the last quarter. Two Sigma Investments LP lifted its position in Compugen by 10.6% in the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 18,929 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 61,202 shares in the last quarter. 12.22% of the stock is currently owned by institutional investors and hedge funds.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.